Zweig DiMenna Associates LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 5,700 shares of the biopharmaceutical company’s stock, valued at approximately $462,000.
A number of other hedge funds have also recently modified their holdings of GILD. FMR LLC raised its stake in shares of Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the period. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. Toronto Dominion Bank grew its holdings in shares of Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after purchasing an additional 75,364 shares in the last quarter. Finally, Fagan Associates Inc. grew its holdings in Gilead Sciences by 2.6% during the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 845 shares in the last quarter. 75.95% of the stock is currently owned by institutional investors.
Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $79.02 to $96.00 in a research report on Tuesday. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Thursday. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Finally, Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective on the stock. in a research note on Wednesday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $85.53.
In other Gilead Sciences news, EVP James R. Meyers sold 100,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the transaction, the executive vice president now owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 591,666 shares of company stock worth $44,466,567. Company insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down $0.57 during trading on Friday, reaching $81.17. 8,527,399 shares of the company’s stock traded hands, compared to its average volume of 8,669,392. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The company has a market capitalization of $105,820.00, a PE ratio of 9.23, a PEG ratio of -1.77 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the business posted $2.75 EPS. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.48 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.56%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
WARNING: This article was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://ledgergazette.com/2018/01/19/zweig-dimenna-associates-llc-buys-new-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.